Anti-CXCR2 antibody-coated nanoparticles with an erythrocyte-platelet hybrid membrane layer for atherosclerosis therapy

Huang, Rongzhong; Zhang, Lujun; Li, Xingsheng; Liu, Fan; Cheng, Xiaoxiao; Ran, Haitao; Wang, Zhigang; Li, Yongyong; Feng, Yakai; Liang, Liwen; Su, Wenhua; Melgiri, N D; Sun, Yang

doi:10.1016/j.jconrel.2023.02.036

Cited by 20 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is found that the HMs obtained by the fusion of different biofilms can integrate the advantages of the parent membrane. For example, the HMs of erythrocytes and platelets are characterized by prolonging the blood circulation time and binding to the pathogen ( Huang et al, 2023a ); the HMs that fuse erythrocytes with cancer cells are endowed with the ability to prolong the half-life and homologous targeting ( Chen et al, 2021a ). In view of the advantages, HMs-derived MBNPs have been widely explored in tumor gene therapy.…”

Section: Application Of Mbnpsmentioning

confidence: 99%

Biomembrane-wrapped gene delivery nanoparticles for cancer therapy

Li,

Zeng,

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

As a promising strategy, gene delivery for cancer treatment accepts encouraging progress due to its high efficacy, low toxicity, and exclusive selectivity. However, the delivery efficiency, specific biological distribution, targeted uptake, and biosafety of naked nucleic acid agents still face serious challenges, which limit further clinical application. To overcome the above bottleneck, safe and efficient functional nanovectors are developed to improve the delivery efficiency of nucleic acid agents. In recent years, emerging membrane-wrapped biomimetic nanoparticles (MBNPs) based on the concept of “imitating nature” are well known for their advantages, such as low immunogenicity and long cycle time, and especially play a crucial role in improving the overall efficiency of gene delivery and reducing adverse reactions. Therefore, combining MBNPs and gene delivery is an effective strategy to enhance tumor treatment efficiency. This review presents the mechanism of gene therapy and the current obstacles to gene delivery. Remarkably, the latest development of gene delivery MBNPs and the strategies to overcome these obstacles are summarized. Finally, the future challenges and prospects of gene delivery MBNPs toward clinical transformation are introduced. The principal purpose of this review is to discuss the biomedical potential of gene delivery MBNPs for cancer therapy and to provide guidance for further enhancing the efficiency of tumor gene therapy.

show abstract

Section: Application Of Mbnpsmentioning

confidence: 99%

Biomembrane-wrapped gene delivery nanoparticles for cancer therapy

Li,

Zeng,

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…In inflammatory states, activated platelets secrete granules containing the chemokine IL-8 (CXCL8), attract circulating monocytes via the ox-LDL-induced chemokine receptor CXCR2, and drive p38α signaling and M1 macrophage polarization via macrophage CXCR2 (Nording, Baron, & Langer, 2020). Huang et al (R. Huang et al, 2023) designed [RBC-P] NPs containing anti-CXCR2 antibodies, namely anti-CXCR2 [RBC-P] NPs. The nanoparticles specifically bound CXCR2 and blocked CXCL8 interaction with CXCR2, suggesting that they could inhibit the platelet-induced, p38α-mediated pro-inflammatory M1 phenotype of plaque macrophages.…”

Section: Hybrid Cell Membranesmentioning

confidence: 99%

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy

Deng,

Ao,

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

Atherosclerosis (AS) is considered to be one of the major causes of cardiovascular disease. Its pathological microenvironment is characterized by increased production of reactive oxygen species, lipid oxides, and excessive inflammatory factors, which accumulate at the monolayer endothelial cells in the vascular wall to form AS plaques. Therefore, intervention in the pathological microenvironment would be beneficial in delaying AS. Researchers have designed biomimetic nanomedicine (nanomedicine) with excellent biocompatibility and the ability to avoid being cleared by the immune system through different therapeutic strategies to achieve better therapeutic effects for the characteristics of AS. Biomimetic nanomedicine can further enhance delivery efficiency and improve treatment efficacy due to their good biocompatibility and ability to evade clearance by the immune system. Biomimetic nanomedicine based on therapeutic strategies such as neutralizing inflammatory factors, ROS scavengers, lipid clearance and integration of diagnosis and treatment are versatile approaches for effective treatment of AS. The review firstly summarizes the targeting therapeutic strategy of biomimetic nanomedicine for AS in recent 5 years. Biomimetic nanomedicine using cell membranes, proteins, and extracellular vesicles as carriers have been developed for AS.

show abstract

“…In addition to NPs, artificial cells created using micro and nanotechnology can be used for personalized treatment . These artificial cells, such as erythrocytes, MCs, and platelets, are designed to be mobile and biocompatible. , They can be engineered to deliver therapeutic agents directly to the plaque site, enhancing the effectiveness of treatment. Composite nanomotors constructed using magnetic iron oxide, magnesium metal, and enzymes are another interesting approach.…”

Section: Introductionmentioning

confidence: 99%

Design and Fabrication of Environmentally Responsive Nanoparticles for the Diagnosis and Treatment of Atherosclerosis

Wang,

Lu,

Yin

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Cardiovascular disease poses a significant threat to human health in today's society. A major contributor to cardiovascular disease is atherosclerosis (AS). The development of plaque in the affected areas involves a complex pathological environment, and the disease progresses rapidly. Nanotechnology, combined with emerging diagnostic and treatment methods, offers the potential for the management of this condition. This paper presents the latest advancements in environment-intelligent responsive controlled-release nanoparticles designed specifically for the pathological environment of AS, which includes characteristics such as low pH, high reactive oxygen species levels, high shear stress, and multienzymes. Additionally, the paper summarizes the applications and features of nanotechnology in interventional therapy for AS, including percutaneous transluminal coronary angioplasty and drug-eluting stents. Furthermore, the application of nanotechnology in the diagnosis of AS shows promising real-time, accurate, and continuous effects. Lastly, the paper explores the future prospects of nanotechnology, highlighting the tremendous potential in the diagnosis and treatment of atherosclerotic diseases, especially with the ongoing development in nano gas, quantum dots, and Metal−Organic Frameworks materials.

show abstract

Anti-CXCR2 antibody-coated nanoparticles with an erythrocyte-platelet hybrid membrane layer for atherosclerosis therapy

Cited by 20 publications

References 46 publications

Biomembrane-wrapped gene delivery nanoparticles for cancer therapy

Biomembrane-wrapped gene delivery nanoparticles for cancer therapy

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy

Design and Fabrication of Environmentally Responsive Nanoparticles for the Diagnosis and Treatment of Atherosclerosis

Contact Info

Product

Resources

About